Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
GERN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.46 - $5.34
Previous CloseN/A
Volume1.63M
Average Volume (3M)18.11M
Market Cap
$1.01B
Enterprise Value$2.19B
Total Cash (Recent Filing)$36.69M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.01
Next Earnings
May 07, 2025EPS Estimate
-0.03Last Dividend Ex-Date
Jul 22, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding636,904,500
10 Day Avg. Volume13,351,412
30 Day Avg. Volume18,111,727
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15.06
Price to Cash Flow (P/CF)-6.60
P/FCF Ratio0.00
Enterprise Value/Market Cap2.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit28.91
Enterprise Value/Ebitda-14.14
Forecast
1Y Price Target
$4.50Price Target Upside204.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Geron News
See All GERN News
---
Bulls Say, Bears Say
Bulls Say
Market ExclusivityGeron anticipates market exclusivity for Rytelo in the EU until 2038.
Regulatory ApprovalThe European Commission approved Rytelo for certain patients, enhancing its clinical profile.
Strategic PartnershipsGeron plans to commercialize Rytelo in select EU countries and is open to partnering for sales outside the US.
Bears Say
Launch PerformanceInvestors are reluctant to put much stake in this absent drastic change.
Management UncertaintyThe search for a new CEO could bring uncertainty to the company's strategic direction.
Revenue ConcernsRecent announcement of flat Rytelo revenues following 4Q24 earnings call.
---
Ownership Overview
0.09% Insiders
12.46% Mutual Funds
31.92% Other Institutional Investors
40.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.46 and its highest was $5.34 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $1.01B.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is May 07, 2025 which is in 34 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Feb 26, 2025. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.025 by -$0.015.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.149 which represents an annual dividend yield of N/A. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -0.03.
How many shares outstanding does Geron Corp have?
Geron Corp has 636,904,500 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.025. Following the earnings report the stock price went down -32.068%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GERN
---
Geron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (204.05% Upside)
$4.50 (204.05% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 90%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $206.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.81%
12-Months-Change
Fundamentals
Return on Equity
-66.09%
Trailing 12-Months
Asset Growth
50.85%
Trailing 12-Months
Company Description
Geron Corp
Geron Corporation is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. The company operates in the biopharmaceutical sector, with a primary emphasis on its telomerase inhibitor program. Geron's lead product, imetelstat, is a first-in-class telomerase inhibitor currently being developed for hematologic myeloid malignancies.
---
GERN Company Deck
---
GERN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights significant achievements such as FDA approval and strong cash reserves, but also emphasizes challenges like flat revenue trends and the need for strategic adjustments. The sentiment is mixed, with both positive progress and areas needing improvement.Read More>---
GERN Stock 12 Month Forecast
Average Price Target
$4.50
▲(204.05% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Viridian Therapeutics
―
Spyre Therapeutics
―
Pulse Biosciences
―
Enliven Therapeutics
―
Best Analysts Covering GERN
1 Year
---